A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

Authors

Stuart J. Schnitt (ORCID: https://orcid.org/0000-0002-3608-7828)
Melissa E. Hughes (ORCID: https://orcid.org/0000-0001-6190-9101)
Shom Goel (ORCID: https://orcid.org/0000-0001-8329-9084)
Elizabeth A. Mittendorf (ORCID: https://orcid.org/0000-0002-9762-8536)
Bojana Jovanović (ORCID: https://orcid.org/0000-0002-6971-4525)
Molly K. DiLullo (ORCID: https://orcid.org/0009-0005-1036-796X)
Xiangying Chu (ORCID: https://orcid.org/0009-0000-3474-3804)
Eileen Wrabel
Timothy K. Erick (ORCID: https://orcid.org/0000-0002-6855-2528)
Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
Rinath M. Jeselsohn (ORCID: https://orcid.org/0000-0001-7996-7529)
Douglas Russo (ORCID: https://orcid.org/0000-0002-2502-1540)
Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)

Institutions

Brigham and Women's Hospital (US)
Harvard University (US)
The University of Melbourne (AU)
Dana-Farber Cancer Institute (US)
Dana-Farber/Harvard Cancer Center (US)
Dana-Farber Brigham Cancer Center (US)

Publication Details

Journal: Clinical Cancer Research
Published: 2025-02-05
DOI: https://doi.org/10.1158/1078-0432.ccr-24-2647
Citations: 7
Primary Topic: Advanced Breast Cancer Therapies
Type: article
Field-Weighted Citation Impact: 10.63

Funders

Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Sanofi
Gilead Sciences
Jazz Pharmaceuticals
Mersana Therapeutics
BeiGene
Incyte
Carrick Therapeutics
Moderna
G1 Therapeutics
Seagen
Natera
Bayer HealthCare
Eisai
Snow Medical
Genentech
Medical Research Council
National Health and Medical Research Council
Janssen Pharmaceuticals
Daiichi Sankyo Europe

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

Stuart J. Schnitt, Melissa E. Hughes, Shom Goel, Elizabeth A. Mittendorf et al.

Feb 5, 2025

7 citations

Clinical Cancer Research

Advanced Breast Cancer Therapies

10.63

article

A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer

Stuart J. Schnitt, Melissa E. Hughes, Shom Goel, Elizabeth A. Mittendorf, Bojana Jovanović, Molly K. DiLullo, Xiangying Chu, Eileen Wrabel, Timothy K. Erick, Nancy U. Lin, Rinath M. Jeselsohn, Douglas Russo, Nabihah Tayob, Sara M. Tolaney

February 5, 2025article en

7 citations

Abstract

No abstract available for this paper.

Clinical Cancer ResearchVol. 31(8)

Brigham and Women's Hospital (US), Harvard University (US), The University of Melbourne (AU), Dana-Farber Cancer Institute (US), Dana-Farber/Harvard Cancer Center (US), Dana-Farber Brigham Cancer Center (US)

Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Jazz Pharmaceuticals, Mersana Therapeutics, BeiGene, Incyte, Carrick Therapeutics, Moderna, G1 Therapeutics, Seagen, Natera, Bayer HealthCare, Eisai, Snow Medical, Genentech, Medical Research Council, National Health and Medical Research Council, Janssen Pharmaceuticals, Daiichi Sankyo Europe

Good health and well-being

Openalex Percentile: Top 2%

Advanced Breast Cancer Therapies

10.63

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.